Individuals diagnosed with thyroid cancer at a younger age have a higher risk of hypertension, swelling around the heart, and osteoporosis compared with individuals diagnosed at an older age, according to a study presented at the 2017 Cancer Survivorship Symposium (CSS 2017) held in San Diego, California, US.
Warfarin is effective in preventing stroke in patients with atrial fibrillation (AF), but the potential benefits are not always borne out in clinical practice as patients are often not adequately anticoagulated. Non-vitamin K antagonist oral anticoagulants (NOACs) are promising alternatives with proven efficacy and safety in stroke prevention in AF and are easier to administer. At a Daiichi Sankyo-sponsored symposium organized by the Hong Kong College of Cardiology, Professor Stuart Connolly of the McMaster University, Ontario, Canada, discussed the potential benefits of NOACs for AF patients. In particular, he highlighted the beneficial trade-off between stroke prevention and bleeding risk offered by the NOAC edoxaban (Lixiana™, Daiichi Sankyo) in elderly patients with AF, the patient population with the highest stroke risk.